REFERENCES

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

OnabotulinumtoxinA for Injection (Botox): For the Treatment of Overactive Bladder [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul.

Cover of OnabotulinumtoxinA for Injection (Botox)

OnabotulinumtoxinA for Injection (Botox): For the Treatment of Overactive Bladder [Internet].

Show details

Contents

< Prev Next >

REFERENCES

1.: Common Drug Review. CDEC final recommendation: onabotulinumtoxinA (Botox - Allergan Inc.). Indication: neurogenic detrusor overactivity [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); Jul 19, 2012. [cited 2014 Aug 27]. Available from: http://www.cadth.ca/media/cdr/complete/cdr_complete_Botox_July-23-12.pdf.
2.: Pharmacoeconomic evaluation. CDR submission: BOTOX^® (onabotulinumtoxinA) 100 U in the management of refractory urinary incontinence (UI) due to overactive bladder (OAB). Company: Allergan Inc. [CONFIDENTIALmanufacturer's submission]. Markham (ON): Allergan Inc; 2013.
3.: Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a b3-Adrenoceptro agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63:283–295. [PubMed: 23182126]
4.: Clinical Study Report: 191622-095. A multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the safety and efficacy of a single treatment of BOTOX^® (botulinum toxin type A) purified neurotoxin complex followed by a treatment with BOTOX^® as applicable in patients with idiopathic overactive bladder with urinary incontinence [CONFIDENTIALinternal manufacturer's report]. Irvine (CA): Allergan, Inc.; Jan 10, 2012.
5.: Clinical Study Report: 191622-520. A multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the safety and efficacy of a single treatment of BOTOX^® (botulinum toxin type A) purified neurotoxin complex followed by a treatment with BOTOX^® as applicable in patients with idiopathic overactive bladder with urinary incontinence [CONFIDENTIALinternal manufacturer's report]. Irvine (CA): Allergan, Inc; Jan 26, 2012.
6.: Clinical Study Report: 191622-096. A multicenter, long-term follow-up study of the safety and efficacy of BOTOX (botulinum toxin type A) purified neurotoxin complex in patients with idiopathic overactive bladder with urinary incontinence [CONFIDENTIALinternal manufacturer's report]. Irvine (CA): Allergan Inc; 2012.
7.: ^PrBOTOX^® (OnabotulinumtoxinA for injection Ph. Eur.): Clostridium botulinum type A neurotoxin complex (900kD) sterile vacuum-dried concentrate powder for solution for injection 50, 100 and 200 Allergan units per vial [product monograph]. Markham (ON): Allergan, Inc; 2013.
8.: Kay S, Tolley K, Colayco D, Khalaf K, Anderson P, Globe D. Mapping EQ-5D utility scores from the Incontinence Quality of Life Questionnaire among patients with neurogenic and idiopathic overactive bladder. Value Health. 2013 Mar;16(2):394–402. [PubMed: 23538192]
9.: Medical Advisory Secretariat. Sacral nerve stimulation for urinary urge incontinence, urgency-frequency, urinary retention, and fecal incontinence: an evidence-base analysis. Ontario Health Technol Assess Series [Internet]. 2005 Mar;5(3) [cited 2014 Aug 13]; Available from: http://www.hqontario.ca/english/providers/program/mas/tech/reviews/pdf/rev_sns_030105.pdf. [PMC free article: PMC3382408] [PubMed: 23074472]
10.: Ontario Health Technology Advisory Committee. Advancing health: Evidence-based advice on health technology. OHTAC 2009 progress report. Toronto (ON): Medical Advisory Secretariat; 2010. [cited 2014 Aug 13]. Sacral nerve stimulation for urinary urge incontinence, urgency-frequency, urinary retention, and fecal incontinence [Internet] Available from: www.health.gov.on.ca/english/providers/program/ohtac/pdf/progress/2009/sns_urinary_en.pdf.
11.: Bettez M, Tu LM, Carlson K, Corcos J, Gajewski J, Jolivet M, et al. 2012 update: guidelines for adult urinary incontinence collaborative consensus document for the Canadian Urological Association. Can Urol Assoc J. 2012;6(5):354–363. [PMC free article: PMC3478335] [PubMed: 23093627]
12.: Botulinum toxin type A powder for solution for injection (BOTOX^®) [Internet]. Glasgow, UK: Scottish Medicines Consortium; Jun 6, 2014. [cited 2014 Jul 10]. Available from: https://www.scottishmedicines.org.uk/files/advice/botulinum_toxin_type_A_Botox_FINAL_June_2014_for_website.pdf.
13.: Pharmaceutical Benefits Advisory Committee. Botulinum toxin type A, 100 units injection, vial, Botox^® [Internet]. Canberra (AU): Department of Health, Australian Government; Nov., 2013. [cited 2014 Jul 10]. Available from: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-11/botulinum.

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK349304

Contents

< Prev Next >

PubReader
Print View
Cite this Page
OnabotulinumtoxinA for Injection (Botox): For the Treatment of Overactive Bladder [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul. REFERENCES.